NCT05476679CompletedPhase 1
An Open Label Phase 2 Study to Evaluate the Effects of a Local Anesthetic, Anti-inflammatory Medications and Compression Garments on RZL-012-Induced Adverse Events
Raziel Therapeutics Ltd.1 site in 1 country48 target enrollmentStarted: September 25, 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Raziel Therapeutics Ltd.
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- Safety - Adverse Events Follow up
Study Overview
Brief Summary
This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:
Detailed Description
In the first stage of the study, 5 subjects will be randomized into each of the treatment groups. Study outcomes will be assessed up to one week thereafter to determine the need to modify additional study treatments. Subsequently up to 10 additional subjects will be randomized into each of the treatment groups for the second stage of the study.
For each subject, the study will consist of a screening period, baseline period in which subjects will receive a single treatment session of RZL-012 and a follow-up period. RZL-012 will be administered during a single treatment session via multiple injections into the submental area under the chin. Subjects will thereafter be monitored for safety and efficacy for at least 84 days.
Each subject will be treated with the same dose of RZL-012 :
• RZL-012 (concentration of injected solution 50 mg/mL RZL-012) of 7.5 mg/0.15 mL/injection point that results in a total dose/volume of 240±30mg mg/4.8±0.6 mL RZL-012, Each subject will receive additional study treatments in accordance with the treatment group to which the subject is randomized.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Is a male or female subject between the ages of 18 and 65 years, inclusive.
- •Has body mass index (BMI) between >22 kg/m2 and <40 kg/m
- •Has SMF bulge that is contiguous and fits to 32±4 injections sites according to a grid with 1 centimeter (cm) distance between injection points.
- •Has grade 3 to 4 of SMF as rated by both the C-CAT and S-CAT.
- •Has stable weight, with no fluctuation of >5 kg in the past 12 months.
- •If female, is not pregnant or breastfeeding based on the following:
- •agree to the use of highly effective contraceptive methods for at least 2 weeks before baseline until 4 weeks after the last day of study drug and a negative serum pregnancy test (ß-hCG) at screening and negative urine pregnancy test at baseline; or
- •is of nonchildbearing potential defined as clinically infertile as the result of surgical sterilization (hysterectomy, bilateral tubal ligation, and/or bilateral oophorectomy); or
- •is confirmed postmenopausal status (defined as either having amenorrhea for ≥ 12 consecutive months without another cause and documented serum follicle-stimulating hormone (FSH) level > 40 mIU/mL or another documented medical condition (e.g., was born without a uterus)) NOTE: The following are considered highly effective contraceptive methods: hormonal oral contraceptives, injectables, and patches; intrauterine devices; double-barrier methods (synthetic condom, diaphragm, or cervical cap used with spermicidal foam, cream, or gel); and male partner sterilization.
- •If male (with or without vasectomy), agree to the use of highly effective contraceptive methods as listed above in criteria 7 as well as to use a barrier method, e.g. condom , from study check-in until 7 days after drug injection.
- •Is willing to avoid strenuous exercise for seven (7) days post treatment.
- •Is able to adhere to the visit schedule and protocol requirements and be available to complete the study.
- •Is willing and able to sign an Institutional Review Board (IRB) approved informed consent form (ICF) indicating that they are aware of the investigational nature of the study.
Exclusion Criteria
- •Is unable to tolerate subcutaneous injections.
- •Has dysfunctional gallbladder activity (e.g., underwent cholecystectomy or cholecystitis).
- •Has any systemic disease including but not limited to gastritis or ulcers, renal dysfunction, hypertension, liver disease, glaucoma, diabetes and/or cardiovascular disease.
- •Has any contraindications to oral corticosteroids (prednisone), NSAIDs (e.g., Celecoxib) or non-sedative antihistamines (e.g. Zyrtec)
- •Has skin laxity (i.e., elastosis, skin crepiness, skin redundancy, skin draping, vertical and/or horizontal skin bands and folds, blunting of cervical mental angle, loss of opposition of skin to underlying neck structures due to skin laxity) that could obscure the evaluation and treatment of SMF.
- •Has any scars, unshaven hair, tattoos, facial hair or jewelry on or near the proposed treatment area.
- •Has presence of structures or confounding factors that may interfere with assessing SMF such as but not limited to enlarged submandibular salivary and/or parotid glands, micrognanthia, chin implant, soft tissue volume augmentation of chin and/or jawline, pronounced platysmal bands and deep necklace lines or presence of facial jowls that could obscure the evaluation of SMF.
- •Has a fat bulge under the chin that is too large to be adequately treated by 32±4 contiguous injections on a 1cm grid .
- •Has a fat bulge under the chin that is of an insufficient volume to allow 32±4 injections within a contiguous 1 cm grid.
- •Has significant history or current evidence of a medical, psychological or other disorder that, in the Investigator's opinion, would preclude enrollment in the study.
- •Has an active bacterial, fungal, or viral infection in the proposed treatment area.
- •Has a pre-existing skin condition in the submental region that, at the Investigator's discretion, may confound evaluation or analysis.
- •Has previously had treatments or surgery in the submentum, such as but not limited to, focused ultrasound, radiofrequency, cryolipolysis, liposuction, sodium deoxycholate, or neck lift.
- •Has pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia, or facial nerve palsy.
- •Has Dercum's Disease.
- •Has allergic reactions to injectables
- •Has allergic reactions to Zyrtec or Celecoxib.
- •Has any pre-existing medical condition other than increased SMF that, at the Investigator's discretion, may result in increased submental fullness, such as but not limited to, thyroid enlargement, goiter, cervical lymphadenopathy, etc.
- •Has a planned fat reduction procedure of any variety to the submental region for the duration of the study.
- •Has medication or a history of coagulopathy.
- •Has a history or family history of venous thrombotic disease.
- •Has been treated chronically at least three (3) months prior to study entry with systemic steroids or immunosuppressive drugs.
- •Has been treated chronically at least one (1) week prior to study entry with non-steroidal anti-inflammatory drugs (NSAIDs)
- •Has used anticoagulation therapies that may increase bleeding or bruising (i.e., aspirin, ibuprofen/Celecoxib, warfarin, vitamins, and herbal preparations) for seven (7) days prior to treatment.
- •.Has had treatment with botulinum toxin injections in the neck or chin area within nine (9) months prior to screening.
- •Current participation or participation within three (3) months prior to the start of this study in a drug or other investigational research study.
Arms & Interventions
RZL-012 50mg/ml
Experimental
Intervention: RZL-012+Celecoxib+Zyrtec (Drug)
RZL-012 50mg/ml
Experimental
Intervention: RZL-012+facial and neck wrap (Drug)
RZL-012 50mg/ml
Experimental
Intervention: RZL-012 (Drug)
RZL-012 50mg/ml
Experimental
Intervention: RZL-012+Lidacaine injection prior treatment (Drug)
RZL-012 50mg/ml
Experimental
Intervention: RZL-012+Medrol (Drug)
Outcomes
Primary Outcomes
Safety - Adverse Events Follow up
Time Frame: 84 days
Number of subjects with severe swelling in each subgroup
Secondary Outcomes
- Efficacy -Reduction in Score According to Clinician Chin Assessment Tool (C-CAT)(84 days)
- Efficacy - Percentage of Change From Baseline in Submental Fat Volume(84 days)
- Efficacy - Number of Participants With 1 Grade Improvement According to the Subject Chin Assessment Tool (S-CAT)(84 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerALK Fusion Protein ExpressionAdjuvant TherapyNon-Small Cell Lung CancerNCT05186506Sichuan University152
Completed
Phase 2
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With PemphigusPemphigus VulgarisPemphigus FoliaceusNCT03334058argenx34
Active, not recruiting
Phase 2
PMT for MDRO DecolonizationMultidrug Resistant Bacterial InfectionEnterobacteriaceae InfectionsPseudomonas AeruginosaVRE InfectionMethicillin-resistant Staphylococcus AureusNCT05632315University of Pennsylvania32
Completed
Phase 2
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Leukemia, Lymphocytic, Chronic, B-CellNCT04204057Rhizen Pharmaceuticals SA21
Recruiting
Phase 2
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLACUTE LYMPHOBLASTIC LEUKEMIANCT05748171Pfizer100